Stavudine entrapped lipid nanoparticles for targeting lymphatic HIV reservoirs

Pharmazie

Volumn 66, Issue 4, 2011, Pages 264-271

  Shegokar, R ^a,b   Singh, K K ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b SNDT WOMEN S UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

SOLID LIPID NANOPARTICLE; STAVUDINE; TECHNETIUM 99M;

ARTICLE; CELL TRANSPORT; CELL VIABILITY; DISEASE CARRIER; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SAFETY; DRUG SOLUTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOID TISSUE; MACROPHAGE; PARTICLE SIZE; SPLEEN; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTI-HIV AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL SURVIVAL; COLORING AGENTS; DRUG COMPOUNDING; ELECTROCHEMISTRY; FLUORESCENT DYES; HIV; HIV SEROPOSITIVITY; LYMPHATIC SYSTEM; MACROPHAGES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; RHODAMINE 123; STAVUDINE; TETRAZOLIUM SALTS; THIAZOLES; TISSUE DISTRIBUTION;

EID: 79957638183     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0149     Document Type: Article

References (29)

1. Al-Haj N, Rasedee A (2009) Solid lipid nanoparticles preparation and characterization. Int J Pharmacol 5: 90-93.
2. Amiji MM, Vyas TK, Shah LK (2006) Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov Med 6: 157-162.
3. Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A (2002) Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 243: 93-105.
4. Daemen T (1992) Activation of Kupffer cell tumoricidal activity by immunomodulators encapsulated in liposomes. Res Immunol 143: 211-214.
5. Desormeaux A, Bergeron MG (2005) Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol 391: 330-351. (Pubitemid 40254044)
6. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE (2006) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835.
7. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE (2007) Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358: 148-158. (Pubitemid 46048870)
8. Escobar Y, Venturelli CR, Escobar-Islas E, Hoyo-Vadillo C (2003) Pharmacokinetics of stavudine by oral administration to healthy Mexican volunteers. Proc West Pharmacol Soc 46: 109-110. (Pubitemid 37463445)
9. Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS (2006) Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 7: 77.
10. Gordon R, Bjorklund NK, Smith RJ, Blyden ER (2009) Halting HIV/AIDS with avatars and havatars: a virtual world approach to modelling epidemics. BMC Public Health 9 Suppl 1: S13.
11. Guimaraes NN, de Andrade HH, Lehmann M, Dihl RR, Cunha KS (2010) The genetic toxicity effects of lamivudine and stavudine antiretroviral agents. Expert Opin Drug Saf.
12. Hou D, Xie C, Huang K, Zhu C (2003) The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24: 1781-1785. (Pubitemid 36184733)
13. Huang M, Wu W, Qian J, Wan DJ, Wei XL, Zhu JH (2005) Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles. Acta Pharmacol Sin 26: 1512-1518. (Pubitemid 41789542)
14. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P (2008) Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4: 41-48. (Pubitemid 351324205)
15. Jayagopal A, Sussman EM, Shastri VP (2008) Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans Nanobioscience 7: 28-34.
16. Kuo YC (2005) Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharm 290: 161-172.
17. Lanao JM, Briones E, Colino CI (2007) Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target 15: 21-36. (Pubitemid 47161329)
18. Lecaroz C, Blanco-Prieto MJ, Burrell MA, Gamazo C (2006) Intracellular killing of Brucella melitensis in human macrophages with microsphere- encapsulated gentamicin. J Antimicrob Chemother 58: 549-556. (Pubitemid 44288118)
19. Lee CM, Choi Y, Huh EJ, Lee KY, Song HC, Sun MJ, Jeong HJ, Cho CS, Bom HS (2005) Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother Radiopharm 20: 620-628. (Pubitemid 43099612)
20. Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J (1998) Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 50: 21-30. (Pubitemid 28044097)
21. Mehnert W, Mader K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47: 165-196. (Pubitemid 32324113)
22. Nassimi M, Schleh C, Lauenstein HD, Hussein R, Lubbers K, Pohlmann G, Switalla S, Sewald K, Muller M, Krug N, Muller-Goymann CC, Braun A (2009) Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal Toxicol 21 Suppl 1: 104-109.
23. Patil RR, Gaikwad RV, Samad A, Devarajan PV (2008) Role of Lipids in Enhancing Splenic Uptake of Polymer-Lipid (LIPOMER) Nanoparticles Journal of Biomedical Nanotechnology 4: 359-366.
24. 99mTc] technetium-labeled liposomes in normal and tumour-bearing rats. Biochem Soc Trans 5: 190-229.
25. Schafer V, von Briesen H, Andreesen R, Steffan AM, Royer C, Troster S, Kreuter J, Rubsamen-Waigmann H (1992) Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm Res 9: 541-546.
26. Sosnik A, Chiappetta DA, Carcaboso AM (2009) Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 138: 2-15.
27. Vyas SP, Subhedar R, Jain S (2006a) Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 58: 321-326. (Pubitemid 43344574)
28. Vyas TK, Shah L, Amiji MM (2006b) Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 3: 613-628. (Pubitemid 44383489)
29. zur Muhlen A, Schwarz C, Mehnert W (1998) Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45: 149-155.